Tonix Pharmaceuticals, Inc.’s (NASDAQ: TNXP) ($TNXP) interview with Dr. Seth Lederman, MD, and CEO.


New to The Street’s TV Host Jane King, from the Nasdaq Marketplace studio, welcomes back Dr. Seth Lederman, MD, CEO at Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP), a clinical-stage biopharmaceutical Company. Dr. Lederman provides a corporate update on its clinical study on patents afflicted with Long-Covid. At the onset of the study, Long-covid symptoms appear heterogeneous, meaning they are not similar among those afflicted. However, the four main symptoms of Fibromyalgia, multi-site pain, fatigue, cognitive problems (Brain Fog), and sleep issues, are also typical with Long-Covid patients. 2/3 of Long-Covid patients have these overlapping symptoms common with Fibromyalgia. Tonix’s TNX-102 SL completed its Fibromyalgia FDA Phase 3 and is moving forward with the FDA for new drug approval. Dr. Lederman believes it could be about another year before FDA drug approval contingent on successful Phase 3 reconfirmation results. Tonix is moving forward with a Long-Covid prevail study for its TNX-102 SL to be completed in the first half of 2023 with the expectation of enrolling 470 patients in a double-blind, randomized placebo study. The results on these 470 people should give Tonix data showing that the TNX-102 SL can help those with Long-Covid. With each successful TNX-102 SL Long Covid study/trial, the Company expects to continue forward with the necessary FDA approvals. The economic hardships for individuals and the overall economy are a massive expense. President Biden, in April 2022, signed an Executive memo for all branches of Government to come up with a national response to handle Long-Covid. A Harvard health economist expects the economic losses to be around $3.7T. 20-30% of those who recovered from Covid now appear to have Long-Covid symptoms, which can last months or years. Doctors who don’t understand the problem are treating patients with opioid based drugs, which don’t help and could cause addiction issues. TNX-102 SL is non-addictive, has no opioid compounds, and improves sleep quality. The Fibromyalgia studies show that sleep quality is important to reducing fibromyalgia symptoms; the same quality sleep might be the key to resolving Long-Covid issues. The on-screen QR code is available during the show; download or visit Tonix Pharmaceuticals, Inc. –

To make sure you never miss a video from New to the Street, click here to subscribe:

Follow New to the Street on Twitter:

Follow New to the Street on Facebook:

Follow New to the Street on Instagram:

Follow New to the Street on Rumble:

About New to the Street:

Subscribe to our Mailing List: